Literature DB >> 11498510

Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix.

P Vertongen1, R M Solano, J Perret, I Langer, P Robberecht, M Waelbroeck.   

Abstract

1. We investigated the role of two conserved basic residues in the second transmembrane helix arginine 172 (R172) and lysine 179 (K179) of the VPAC(2) receptor. 2. Vasoactive intestinal polypeptide (VIP) activated VPAC(2) receptors with an EC(50) value of 7 nM, as compared to 150, 190 and 4000 nM at R172L, R172Q and K179Q-VPAC(2) receptors, respectively. It was inactive at K179I mutated VPAC(2) receptors. These results suggested that both basic residues were probably implicated in receptor recognition and activation. 3. The VPAC(2)-selective VIP analogue, [hexanoyl-His(1)]-VIP (C(6)-VIP), had a higher affinity and efficacy as compared to VIP at the mutated receptors. 4. VIP, Asn(3)-VIP and Gln(3)-VIP activated adenylate cyclase through R172Q receptors with EC(50) values of 190, 2 and 2 nM, respectively, and through R172L receptors with EC(50) values of 150, 12 and 8 nM, respectively. Asn(3)-VIP and Gln(3)-VIP behaved as partial agonists at the wild type receptor, with E(max) values (in per cent of VIP) of 75 and 52%, respectively. In contrast, they were more efficient than VIP (E(max) values of 150 and 150% at the R172Q VPAC(2) receptors, and of 400 and 360% at the R172L receptors, respectively). These results suggested that the receptor's R172 and the ligand's aspartate 3 are brought in close proximity in the active ligand-receptor complex. 5. The K179I and K179Q mutated receptors had a lower affinity than the wild-type receptors for all the agonists tested in this work: we were unable to identify the VIP amino acid(s) that interact with K179.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11498510      PMCID: PMC1621147          DOI: 10.1038/sj.bjp.0704195

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Role of charged amino acids conserved in the vasoactive intestinal polypeptide/secretin family of receptors on the secretin receptor functionality.

Authors:  E Di Paolo; J P Vilardaga; H Petry; N Moguilevsky; A Bollen; P Robberecht; M Waelbroeck
Journal:  Peptides       Date:  1999       Impact factor: 3.750

2.  Measurement of agonist and antagonist ligand-binding parameters at the human parathyroid hormone type 1 receptor: evaluation of receptor states and modulation by guanine nucleotide.

Authors:  S R Hoare; G de Vries; T B Usdin
Journal:  J Pharmacol Exp Ther       Date:  1999-06       Impact factor: 4.030

Review 3.  Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors.

Authors:  D Colquhoun
Journal:  Br J Pharmacol       Date:  1998-11       Impact factor: 8.739

4.  Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.

Authors:  P Gourlet; J Rathé; P De Neef; J Cnudde; M C Vandermeers-Piret; M Waelbroeck; P Robberecht
Journal:  Eur J Pharmacol       Date:  1998-07-31       Impact factor: 4.432

5.  Site-directed mutagenesis of human VIP1 versus VIP2 receptors.

Authors:  P Nicole; K Du; A Couvineau; M Laburthe
Journal:  Ann N Y Acad Sci       Date:  1998-12-11       Impact factor: 5.691

6.  GPCRDB: an information system for G protein-coupled receptors.

Authors:  F Horn; J Weare; M W Beukers; S Hörsch; A Bairoch; W Chen; O Edvardsen; F Campagne; G Vriend
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

7.  The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.

Authors:  P Gourlet; P Vertongen; A Vandermeers; M C Vandermeers-Piret; J Rathe; P De Neef; M Waelbroeck; P Robberecht
Journal:  Peptides       Date:  1997       Impact factor: 3.750

Review 8.  Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland.

Authors:  S R Rawlings; M Hezareh
Journal:  Endocr Rev       Date:  1996-02       Impact factor: 19.871

9.  Lysine 173 residue within the first exoloop of rat secretin receptor is involved in carboxylate moiety recognition of Asp 3 in secretin.

Authors:  J P Vilardaga; E di Paolo; P de Neef; M Waelbroeck; A Bollen; P Robberecht
Journal:  Biochem Biophys Res Commun       Date:  1996-01-26       Impact factor: 3.575

Review 10.  International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.

Authors:  A J Harmar; A Arimura; I Gozes; L Journot; M Laburthe; J R Pisegna; S R Rawlings; P Robberecht; S I Said; S P Sreedharan; S A Wank; J A Waschek
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

View more
  11 in total

1.  Palmitic acid methyl ester is a novel neuroprotective agent against cardiac arrest.

Authors:  Reggie Hui-Chao Lee; Alexandre Couto E Silva; HarLee E Possoit; Francesca M Lerner; Po-Yi Chen; Rinata Azizbayeva; Cristiane T Citadin; Celeste Yin-Chieh Wu; Jake T Neumann; Hung Wen Lin
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2018-11-23       Impact factor: 4.006

Review 2.  Structural and functional insights into the juxtamembranous amino-terminal tail and extracellular loop regions of class B GPCRs.

Authors:  M Dong; C Koole; D Wootten; P M Sexton; L J Miller
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

3.  Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.

Authors:  K Coopman; R Wallis; G Robb; A J H Brown; G F Wilkinson; D Timms; G B Willars
Journal:  Mol Endocrinol       Date:  2011-08-25

4.  Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand's third residue.

Authors:  Jason Perret; Mélanie Van Craenenbroeck; Ingrid Langer; Pascale Vertongen; Françoise Gregoire; Patrick Robberecht; Magali Waelbroeck
Journal:  Biochem J       Date:  2002-03-01       Impact factor: 3.857

5.  Use of Cysteine Trapping to Map Spatial Approximations between Residues Contributing to the Helix N-capping Motif of Secretin and Distinct Residues within Each of the Extracellular Loops of Its Receptor.

Authors:  Maoqing Dong; Polo C-H Lam; Andrew Orry; Patrick M Sexton; Arthur Christopoulos; Ruben Abagyan; Laurence J Miller
Journal:  J Biol Chem       Date:  2016-01-06       Impact factor: 5.157

6.  Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping.

Authors:  Maoqing Dong; Xiequn Xu; Alicja M Ball; Joshua A Makhoul; Polo C-H Lam; Delia I Pinon; Andrew Orry; Patrick M Sexton; Ruben Abagyan; Laurence J Miller
Journal:  FASEB J       Date:  2012-09-10       Impact factor: 5.191

7.  A Hydrogen-Bonded Polar Network in the Core of the Glucagon-Like Peptide-1 Receptor Is a Fulcrum for Biased Agonism: Lessons from Class B Crystal Structures.

Authors:  Denise Wootten; Christopher A Reynolds; Cassandra Koole; Kevin J Smith; Juan C Mobarec; John Simms; Tezz Quon; Thomas Coudrat; Sebastian G B Furness; Laurence J Miller; Arthur Christopoulos; Patrick M Sexton
Journal:  Mol Pharmacol       Date:  2015-12-23       Impact factor: 4.436

8.  Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide.

Authors:  Rulue Chang; Xin Zhang; Anna Qiao; Antao Dai; Matthew J Belousoff; Qiuxiang Tan; Lijun Shao; Li Zhong; Guangyao Lin; Yi-Lynn Liang; Limin Ma; Shuo Han; Dehua Yang; Radostin Danev; Ming-Wei Wang; Denise Wootten; Beili Wu; Patrick M Sexton
Journal:  J Biol Chem       Date:  2020-05-05       Impact factor: 5.157

9.  Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies.

Authors:  Ingrid Langer
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-30       Impact factor: 5.555

10.  The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling.

Authors:  Rachel L Dods; Dan Donnelly
Journal:  Biosci Rep       Date:  2015-11-23       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.